EU/LA Pearl Index Study - Transdermal Contraceptive Patch

December 4, 2014 updated by: Bayer

Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects

The aim of the present study is to prove efficacy and safety of a new contraceptive patch.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1694

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
    • Buenos Aires
      • Lanus Oeste, Buenos Aires, Argentina, 1824
      • San Isidro, Buenos Aires, Argentina, B1642CLN
    • Ciudad Auton. de Buenos Aires
      • Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1280AEB
      • Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1425ASQ
      • Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina, C1425AWC
    • Santa Fe
      • Rosario, Santa Fe, Argentina, 2000
  • Australia
    • New South Wales
      • Ashfield, New South Wales, Australia, 2031
    • South Australia
      • Adelaide, South Australia, Australia, 5000
      • North Adelaide, South Australia, Australia, 5006
    • Victoria
      • Clayton, Victoria, Australia, 3168
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
  • Chile
      • Santiago, Chile, 7510025
      • Santiago, Chile, 8320165
      • Santiago, Chile, 8350488
      • Temuco, Chile, 4790711
    • Araucanía
      • Temuco, Araucanía, Chile, 4791348
  • France
      • Biarritz, France, 64200
      • Montargis, France, 45200
      • Nimes, France, 30029
      • Quetigny, France, 21800
      • REIMS Cedex, France, 51092
      • Saint Germain En Laye, France, 78100
      • Toulouse, France, 31000
  • Germany
      • Berlin, Germany, 13507
      • Berlin, Germany, 10247
      • Berlin, Germany, 12587
    • Hessen
      • Frankfurt, Hessen, Germany, 60590
    • Nordrhein-Westfalen
      • Aachen, Nordrhein-Westfalen, Germany, 52072
      • Köln, Nordrhein-Westfalen, Germany, 50924
      • Siegen, Nordrhein-Westfalen, Germany, 57072
      • Wuppertal, Nordrhein-Westfalen, Germany, 42103
    • Sachsen
      • Dippoldiswalde, Sachsen, Germany, 01744
      • Dresden, Sachsen, Germany, 01099
      • Leipzig, Sachsen, Germany, 04207
      • Leipzig, Sachsen, Germany, 04299
    • Sachsen-Anhalt
      • Blankenburg, Sachsen-Anhalt, Germany, 38889
      • Jessen, Sachsen-Anhalt, Germany, 06917
      • Magdeburg, Sachsen-Anhalt, Germany, 39104
    • Thüringen
      • Gera, Thüringen, Germany, 07545
  • Italy
      • Bologna, Italy, 40138
      • Cagliari, Italy, 09124
      • Catanzaro, Italy, 88100
      • Firenze, Italy, 50134
      • Modena, Italy, 41124
      • Palermo, Italy, 90127
      • Pavia, Italy, 27100
      • Perugia, Italy, 06156
      • Pisa, Italy, 56126
      • Siena, Italy, 53100
    • Brindisi
      • Francavilla Fontana, Brindisi, Italy, 72021
  • Mexico
      • Chihuahua, Mexico, 31350
      • Mexico D.F., Mexico, 11000
      • México D.F., Mexico, 10700
      • México, D.F., Mexico, 11000
      • San Luis Potosí, Mexico, 78230
    • Coahuila
      • Torreón, Coahuila, Mexico, 27000
  • Spain
      • Barcelona, Spain, 08035
      • Barcelona, Spain, 08013
      • Barcelona, Spain, 08028
      • Lugo, Spain, 27002
      • Pamplona, Spain, 31015
      • Zaragoza, Spain, 50001
    • Cádiz
      • San Fernando, Cádiz, Spain, 11100
    • Pontevedra
      • Vigo, Pontevedra, Spain, 36209
    • Sevilla
      • Dos Hermanas, Sevilla, Spain, 41700
    • Vitoria
      • Alava, Vitoria, Spain, 01004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Requiring contraception
  • Normal cervical smear
  • Smokers not older than 30 years
  • History of regular cyclic menstrual periods

Exclusion Criteria:

  • Pregnancy or lactation
  • Obesity (BMI> 30 kg/m2
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other contraceptive methods than study medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Occurrence of pregnancy
Time Frame: 13 treatment cycles each consisting of 28 days and follow-up period of 14 days
13 treatment cycles each consisting of 28 days and follow-up period of 14 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Cervical smear
Time Frame: 13 treatment cycles each consisting of 28 days
13 treatment cycles each consisting of 28 days
Adverse events
Time Frame: 13 treatment cycles each consisting of 28 days
13 treatment cycles each consisting of 28 days
Bleeding pattern and cycle control
Time Frame: 13 treatment cycles each consisting of 28 days
13 treatment cycles each consisting of 28 days

Other Outcome Measures

Outcome Measure
Time Frame
Treatment compliance
Time Frame: 13 treatment cycles each consisting of 28 days
13 treatment cycles each consisting of 28 days
Subjective assessment of satisfaction with the treatment
Time Frame: 13 treatment cycles each consisting of 28 days
13 treatment cycles each consisting of 28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bayer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

September 1, 2011

Study Registration Dates

First Submitted

May 5, 2009

First Submitted That Met QC Criteria

June 4, 2009

First Posted (Estimate)

June 5, 2009

Study Record Updates

Last Update Posted (Estimate)

December 5, 2014

Last Update Submitted That Met QC Criteria

December 4, 2014

Last Verified

December 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 91554
  • 2008-004214-27 (EudraCT Number)
  • 310801 (Other Identifier: Company internal)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Contraception

Clinical Trials on Ethinylestradiol/Gestodene (BAY86-5016)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe